FA
FATE.US Fate Therapeutics Inc
- Market cap
- USD 156M
- P/E
- -
- P/B
- 1.22x
- ROE
- -92.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FATE.US undervalued?
Graham numberThe Graham number of Fate Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fate Therapeutics Inc fundamental analysis
No fundamental analysis for Fate Therapeutics Inc yet.
Fate Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT…
Full company profileFate Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fate Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.40M | 4.11M | 4.74M | 10.7M | 31.4M | 55.8M | 96.3M | 63.5M | 13.6M | 6.65M | 4.51M |
| Gross Profit | -22.1M | -30.3M | -51.3M | 10.7M | -94.2M | 50.0M | 96.3M | -93.7M | -105M | -6.26M | -2.95M |
| Operating Income | -32.0M | -42.1M | -67.1M | -101M | -128M | -217M | -308M | -191M | -210M | -148M | -129M |
| EBITDA | -30.9M | -40.7M | -63.7M | -94.2M | -125M | -206M | -295M | -143M | -177M | -127M | -114M |
| Net Income | -33.5M | -43.0M | -66.6M | -98.1M | -173M | -212M | -255M | -161M | -186M | -136M | -123M |
| EPS | -1.05 | -1.02 | -1.19 | -1.44 | -2.10 | -2.24 | -2.63 | -1.64 | -1.64 | -1.15 | -0.99 |
| Balance Sheet | |||||||||||
| Total Assets | 95.0M | 105M | 213M | 302M | 622M | 921M | 706M | 506M | 441M | 319M | 238M |
| Total Liabilities | 21.9M | 28.1M | 52.6M | 57.5M | 238M | 243M | 222M | 138M | 122M | 112M | 105M |
| Shareholders' Equity | 73.2M | 77.2M | 160M | 245M | 384M | 679M | 484M | 368M | 319M | 207M | 133M |
| Cash & Short-term Investments | 92.1M | 101M | 201M | 221M | 483M | 616M | 436M | 315M | 279M | 204M | 139M |
| Total Debt | 10.7M | 22.1M | 14.9M | 26.9M | 97.3M | 115M | 109M | 104M | 85.3M | 77.8M | 74.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.8M | -36.9M | -38.7M | -83.2M | -39.2M | -163M | -248M | -132M | -123M | -106M | -110M |
| Capital Expenditure | 457K | 1.73M | 2.30M | 7.40M | 4.93M | 50.7M | 35.6M | 6.15M | 730K | 5.95M | 425K |
| Free Cash Flow | -30.3M | -38.6M | -41.0M | -90.6M | -44.2M | -214M | -284M | -138M | -124M | -112M | -110M |
| Ratios | |||||||||||
| ROE | -45.7% | -55.6% | -41.5% | -40.1% | -45.1% | -31.3% | -52.7% | -43.7% | -58.4% | -65.8% | -92.3% |
| ROA | -35.2% | -40.8% | -31.3% | -32.5% | -27.9% | -23.0% | -36.1% | -31.8% | -42.3% | -42.7% | -51.5% |
| Net Profit Margin | -760.2% | -1,046.1% | -1,405.0% | -919.0% | -551.6% | -379.9% | -264.9% | -253.3% | -1,366.5% | -2,051.1% | -2,722.8% |
| Debt to Equity | 0.15x | 0.29x | 0.09x | 0.11x | 0.25x | 0.17x | 0.23x | 0.28x | 0.27x | 0.38x | 0.56x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fate Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 2.52M | 0.04 | - |
| 2018 | - | - | - |
| 2017 | USD 15.2M | 0.36 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Fate Therapeutics Inc
- Insiders 1.07%
- Institutions 69.91%
- Public & others 29.02%
- Shares outstanding 122M
- Free float 106M
Top funds holding FATE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Strategic Equity Inv | 3.42M | 2.82% | +9.59% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.19M | 2.63% | 0.00% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 1.55M | 1.28% | -1.24% | Sep 2026 |
| Bruce | 989K | 0.81% | 0.00% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 941K | 0.77% | +11.93% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 552K | 0.45% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 512K | 0.42% | -0.38% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 396K | 0.33% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 344K | 0.28% | 0.00% | Oct 2026 |
| Vanguard Market Neutral I | 308K | 0.25% | 0.00% | Jun 2026 |
| Vanguard Health Care ETF | 286K | 0.24% | +0.53% | Sep 2026 |
| AQR Small Cap Multi-Style I | 256K | 0.21% | +31.48% | Jun 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 243K | 0.20% | 0.00% | Oct 2026 |
| BlackRock Advantage Small Cap Gr Instl | 231K | 0.19% | -0.33% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 227K | 0.19% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 193K | 0.16% | -0.05% | Sep 2026 |
| iShares Healthcare Innov ETF USD Acc | 183K | 0.15% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 180K | 0.15% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 162K | 0.13% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 157K | 0.13% | +0.34% | Oct 2026 |
Top institutions holding FATE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Redmile Group, LLC | 12.9M | 10.59% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.30M | 6.00% | -27.51% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.55M | 3.74% | +9.95% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.45M | 3.66% | +6.05% | Jun 2026 |
| Acadian Asset Management LLC | 4.35M | 3.58% | +5.61% | Jun 2026 |
| AQR Capital Management LLC | 3.84M | 3.16% | +27.84% | Jun 2026 |
| Two Sigma Investments LLC | 3.59M | 2.95% | +3.55% | Jun 2026 |
| Johnson & Johnson | 3.38M | 2.78% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 2.98M | 2.45% | +0.29% | Jun 2026 |
| Millennium Management LLC | 2.43M | 2.00% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.05M | 1.69% | +54.33% | Jun 2026 |
| Geode Capital Management, LLC | 1.32M | 1.09% | -48.97% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 1.08M | 0.89% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 1.03M | 0.84% | +58.74% | Jun 2026 |
| Citadel Advisors Llc | 993K | 0.82% | +5.34% | Jun 2026 |
| Bruce & Co Inc | 989K | 0.81% | +25.34% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 695K | 0.57% | -9.53% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 640K | 0.53% | -2.04% | Jun 2026 |
| Charles Schwab Investment Management Inc | 611K | 0.50% | -19.22% | Jun 2026 |
| UBS Group AG | 590K | 0.49% | -67.60% | Jun 2026 |
Fate Therapeutics Inc company profile
- Company name
- Fate Therapeutics Inc
- Ticker
- FATE.US
- Exchange
- USA Stocks
- Listed since
- Oct 1, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 161
- Fiscal year end
- December
- Address
- 12278 Scripps Summit Drive, San Diego, CA, United States, 92131
- Phone
- 858 875 1800
- Website
- fatetherapeutics.com
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics Inc management
10- Dr. Bahram Valamehr M.B.A., Ph.D.President, CEO & Director · born 1977
- Mr. Kamal Adawi M.S., MBACFO & Treasurer · born 1979
- Ms. Cindy R. Tahl J.D.Chief Legal & Compliance Officer and Corporate Secretary · born 1973
- Ms. Jessica FrancisSenior Vice President of Human Resources & Operations
- Dr. Martin HoskingHead of Research
- Dr. Tunde Babalola Ph.D.Senior Vice President of Technical Operations & Quality
- Mr. Ryan DouglasSenior Director of Investor Relations & Business Development
- Mr. Andrew HenrySenior Vice President of Clinical Operations · born 1964
- Dr. Yu Cai J.D., Ph.D.Head of Intellectual Property & Assistant General Counsel
- Mr. James Archie Harrell Jr.Senior Vice President of Market Development & Commercial Operations · born 1970